ArticleBMC infectious diseases2025
Age-specific antibody profiles of respiratory syncytial virus after COVID-19 pandemic: a sero-epidemiological survey in Taizhou City, Eastern China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe generalizability of the current quantitative assessments of age-specific RSV antibody levels remains unclear in China. We aimed to comprehensively understand the RSV immune profile at the population level and identify related factors.
methodsWe conducted a community-based cross-sectional sero-epidemiological study in Taizhou City, Eastern China, from June 2 to 30, 2024, and assessed RSV pre-F IgG antibody titres. We employed generalized linear models to identify factors linked to antibody titres and used a generalized additive model to determine RSV seropositivity risk. The serocatalytic model was further used to estimate the force of infection (FOI) based on age-specific seroprevalence data.
resultsAmong 1303 individuals aged 16 months to 93 years, toddlers (younger than 2 years) had the lowest geometric mean titres (GMTs) of RSV pre-F IgG antibodies, which was 591.9 (95% confidence interval [CI], 106.5-3291.1). The GMTs increased annually by 2.038-fold (0.842-4.011), attaining a titre of 6133.9 (4639.3-8110.2) by the age of 4. The seroprevalence (using titre > 200 as the threshold) surged sharply with age, from 46.1% (42.2-50.2) at 1 year of age to 91.5% (88.9-93.8) at age 4, with an estimated FOI of 0.618 (0.547-0.697). Children residing in households with over four members correlated with a heightened risk of seropositivity within the first 4 postnatal year compared to those in households with four or fewer members (adjusted odds ratio, aOR: 1.954, 1.082-3.529). Age was significantly associated with GMTs in the elderly individuals (aged 65 and above), with an estimated annual increment of 0.019-fold (0.004-0.034). Elderly with underlying diseases demonstrated a 0.203-fold (0.036-0.341) reduction in GMTs compared to those without such conditions.
conclusionsAn early age-dependent pattern in RSV serostatus is observed, and the seroprevalence increased with age. Low antibody titres in early-life period and immunity impairment in the elderly due to underlying diseases emphasize the need to protect younger children and the elderly, from RSV infections. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.